Status: Not yet recruiting
Keywords: Molecularly guided therapy , Refractory Childhood cancers , Neuroblastoma , Brain tumor , Rare tumor
IRB Number: 00061331
Specialty: Pediatric Hematology and Oncology
Primary Objectives: Determine feasibility of using tumor samples to assess genomic mRNA expression arrays and DNA mutation panels using predictive modeling to make real-time treatment decisions for children with relapsed/refractory cancers.
♦ To continue to determine the safety of allowing a molecular tumor board to determine individualized treatment plans
♦ To determine the activity of treatments chosen based on:
• Overall response rate (ORR)
• Progression free survival (PFS)
♦ To explore the relationship between tumor phenotype and response by permitting use of tumor tissue in a correlative biologic study
♦ To compare PFS interval to PFS intervals of previous chemotherapy regimens since relapse for each subject.
This is an open label, multicenter prospective study to evaluate the ability of using genome-wide expression profiles and mutation panels of a child’s tumor to predict individualized therapies for patients.